Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $9.3300 (-2.91%) ($9.1500 - $9.6900) on Fri. Apr. 3, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 7.16% (three month average) | RSI | 74 | Latest Price | $9.3300(-2.91%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD advances 0.9% a day on average for past five trading days. | Weekly Trend | FOLD advances 6.6% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(54%) XBI(51%) IWO(50%) IWM(45%) IWC(44%) | Factors Impacting FOLD price | FOLD will decline at least -3.58% in a week (0% probabilities). VIXM(-26%) VXX(-15%) UUP(-10%) TLT(-5%) UNG(-3%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -3.58% (StdDev 7.16%) | Hourly BBV | 0 () | Intraday Trend | -1.7% | | | |
|
5 Day Moving Average | $9.35(-0.21%) | 10 Day Moving Average | $9.31(0.21%) | 20 Day Moving Average | $8.73(6.87%) | To recent high | -16.4% | To recent low | 40.7% | Market Cap | $2.409b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |